
Aerovate
Developing disease modifying therapies for patients who suffer from pulmonary arterial hypertension.
Market cap
$78.8m
Enterprise value
$633k
Share price
$2.68 AVTE
Authorizing premium user...
Developing disease modifying therapies for patients who suffer from pulmonary arterial hypertension.